Therapeutic trials for subjective cognitive impairment to prevent Alzheimer's disease are feasible and necessary.
Answers are grounded in this paper and cite their sources.
Supports initiation of therapeutic trials in subjective cognitive impairment; leaves open Alzheimer's prevention efficacy.
Studies of therapeutic agents in SCI treatment and resultant Alzheimer's disease prevention appear to be feasible. These trials are also necessary from a public health perspective.
No takes yet. Share an insight, caveat, or question.
Reisberg et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: